Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

OBJECTIVE: We reported previously that empagliflozin—a sodium-glucose cotransporter (SGLT) 2 inhibitor—exhibited preventive effects against obesity. However, it was difficult to extrapolate these results to human subjects. Here, we performed a therapeutic study, which is more relevant to clinical si...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMJ Open Diabetes Res Care
Asıl Yazarlar: Xu, Liang, Nagata, Naoto, Chen, Guanliang, Nagashimada, Mayumi, Zhuge, Fen, Ni, Yinhua, Sakai, Yuriko, Kaneko, Shuichi, Ota, Tsuguhito
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2019
Konular:
Obesity Studies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827766/
https://ncbi.nlm.nih.gov/pubmed/31749970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2019-000783
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller